知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1510 条记录 (耗时 0.052 秒)

    Immunoassay kit for quantification of BNP and proBNP
    73.
    发明授权
    Immunoassay kit for quantification of BNP and proBNP 有权
    用于定量BNP和proBNP的免疫测定试剂盒

    公开(公告)号：US09145459B2

    公开(公告)日：2015-09-29

    申请号：US14689486

    申请日：2015-04-17

    申请人： HYTEST LTD.

    发明人： Natalia N. Tamm ,  Alexey G. Katrukha ,  Vladimir L. Filatov ,  Olga V. Kolosova

    IPC分类号： C07K16/26 ,  G01N33/68 ,  G01N33/74

    CPC分类号： C07K16/26 ,  C07K2317/32 ,  C07K2317/34 ,  G01N33/6887 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/58

    摘要： The present invention relates to an immunoassay for detection of BNP, proBNP and fragments thereof. Essentially the assay comprises: a) contacting the antigen with a first antibody specific to a fragment corresponding to amino acids 11-22 of BNP, or to a part of this peptide comprising at least three amino acids of said sequence, to obtain a first order immune complex. b) contacting the first order immune complex obtained at step (a) with a second antibody recognizing said first order immune complex, to obtain a second order immune complex, wherein said antibody is unable to recognize free BNP, proBNP or free first antibody; c) Detecting the second order immune complex.

    摘要翻译： 本发明涉及用于检测BNP，proBNP及其片段的免疫测定法。 基本上该测定包括：a）使抗原与对应于BNP的氨基酸11-22的片段特异的第一抗体或包含所述序列的至少三个氨基酸的该肽的一部分接触，以获得第一级 免疫复合物。 b）使步骤（a）获得的一级免疫复合物与识别所述一级免疫复合物的第二抗体接触，以获得二级免疫复合物，其中所述抗体不能识别游离BNP，proBNP或游离的第一抗体; c）检测二级免疫复合物。

    Human antibodies to human angiopoietin-like protein 4
    74.
    发明授权
    Human antibodies to human angiopoietin-like protein 4 有权
    人类血管生成素样蛋白的人抗体4

    公开(公告)号：US09120851B2

    公开(公告)日：2015-09-01

    申请号：US13712268

    申请日：2012-12-12

    申请人： Regeneron Pharmaceuticals, Inc.

    发明人： Mark W. Sleeman ,  Viktoria Gusarova ,  Jee H. Kim ,  Gang Chen

    IPC分类号： A61K39/395 ,  C07K16/22 ,  C07K16/26 ,  A61K31/216 ,  A61K45/06 ,  A61K39/00

    CPC分类号： C07K16/26 ,  A61K31/216 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    摘要： A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.

    摘要翻译： 提供了特异性结合和抑制人类血管生成素样蛋白4（hANGPTL4）的人抗体的完全人抗体或抗原结合片段。 人抗hANGPTL4抗体可用于治疗与ANGPTL4相关的疾病或病症，例如高脂血症，高脂蛋白血症和血脂异常，包括高甘油三酯血症，高胆固醇血症，乳糜微血症等。 此外，可以将抗hANGPTL4抗体施用于有需要的受试者，以预防或治疗脂代谢异常是危险因素的疾病或病症。 这些疾病或病症包括心血管疾病，例如动脉粥样硬化和冠状动脉疾病; 急性胰腺炎 非酒精性脂肪性肝炎（NASH）; 糖尿病; 肥胖; 等等。

    COMPOSITIONS AND METHODS FOR TREATING FATTY TISSUE BUILDUP
    76.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING FATTY TISSUE BUILDUP 有权
    用于治疗脂肪组织构建的组合物和方法

    公开(公告)号：US20150166657A1

    公开(公告)日：2015-06-18

    申请号：US14573600

    申请日：2014-12-17

    申请人： The MetroHealth System

    发明人： M. Michael Wolfe ,  Michael O. Boylan

    IPC分类号： C07K16/26

    CPC分类号： C07K16/26 ,  A61K9/0019 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76

    摘要： The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type II diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered. This results in a reduced rate of weight gain and a marked decrease in lipid synthesis and accumulation.

    摘要翻译： 本公开涉及治疗涉及脂肪组织积累的疾病或病症，例如肥胖，代谢综合征，II型糖尿病等。给予含有针对胃抑制多肽的单克隆抗体的组合物。 这导致体重增加速率降低，脂质合成和积累显着降低。

    METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT
    78.
    发明申请
    METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT 审中-公开
    治疗病理学综合征和药物代谢的方法

    公开(公告)号：US20150037347A1

    公开(公告)日：2015-02-05

    申请号：US14519428

    申请日：2014-10-21

    申请人： Oleg llicch Epshtein

    发明人： Oleg Iliich Epshtein

    IPC分类号： C07K16/44 ,  C07K16/24

    CPC分类号： C07K16/44 ,  A61K31/277 ,  A61K39/39583 ,  A61K41/0004 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/00 ,  C07K16/22 ,  C07K16/24 ,  C07K16/241 ,  C07K16/243 ,  C07K16/245 ,  C07K16/246 ,  C07K16/248 ,  C07K16/249 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2806 ,  C07K16/40 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/77

    摘要： A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome.Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation. At that, activated forms of ultra-low doses of antibodies are raised against antigens of exogenous or endogenous origin, against autologous antigens, fetal antigens; anti-idiotypic antibodies are used too.

    摘要翻译： 治疗病理综合征的方法包括向抗原施用超低剂量抗体的活化形式，其中所述活化形式通过反复连续稀释与外部冲击结合获得，并且所述抗原是施用的物质或药剂 影响这种特殊病理综合征的形成机制。 用于治疗病理综合征的药物包含针对抗原的超低剂量的单克隆抗体，多克隆抗体或天然抗体的活化形式，其中所述活化形式通过重复连续稀释和外部治疗（主要基于顺势疗法技术）制备，所述 抗原是作为病理综合征的直接原因或参与调节其形成机制的物质或药物。 在此情况下，针对自身抗原，胎儿抗原，针对外源性或内源性抗原产生超低剂量抗体的活化形式; 也使用抗独特型抗体。

    Compositions and Methods for Reducing CTL Exhaustion
    79.
    发明申请
    Compositions and Methods for Reducing CTL Exhaustion 审中-公开
    减少CTL耗尽的组合物和方法

    公开(公告)号：US20150004175A1

    公开(公告)日：2015-01-01

    申请号：US14364714

    申请日：2012-12-13

    申请人： YALE UNIVERSITY

    发明人： Susan Kaech ,  Jonathan Chen

    IPC分类号： A61K39/395 ,  A61K31/7088 ,  A61K38/02

    CPC分类号： A61K39/3955 ,  A61K31/352 ,  A61K31/397 ,  A61K31/4196 ,  A61K31/7088 ,  A61K38/02 ,  A61K38/177 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/26 ,  C07K16/2812 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2300/00

    摘要： The compositions and methods described herein are useful for diminishing CTL exhaustion in a subject in need thereof, during an immune response to a viral infection or during an immune response to cancer, thereby leading to a greater CTL response against the viral infection or cancer. The invention relates to compositions and methods for the therapeutic intervention of signaling through EP2 and EP4, by inhibiting at least one of EP2, EP4, PGE2, or combinations thereof. The invention also relates to compositions and methods for the therapeutic intervention of signaling through EP2 and EP4, in combination with the therapeutic intervention of signaling through PD-1, by inhibiting at least one of EP2, EP4, PGE2, or combinations thereof, in combination with inhibiting at least one of PD-1, PD-L1, PD-L2, and combinations thereof.

    摘要翻译： 本文描述的组合物和方法可用于在对病毒感染的免疫应答期间或在对癌症的免疫应答期间减少有需要的受试者的CTL耗尽，从而导致针对病毒感染或癌症的更大的CTL应答。 本发明涉及通过EP2和EP4进行信号传导治疗性干预的组合物和方法，通过抑制EP2，EP4，PGE2或其组合中的至少一种。 本发明还涉及通过EP2和EP4进行信号传导的治疗性干预的组合物和方法，与通过PD-1的信号传导的治疗干预组合通过组合抑制EP2，EP4，PGE2或其组合中的至少一种组合 抑制PD-1，PD-L1，PD-L2及其组合中的至少一种。